Locations
United States · Rockville, MD, USA · North America · Washington, DC, USA · Rockland, Rockville, MD, USA
industry
Biotechnology
Size
201-1000 employees
Stage
IPO
founded in
2008
REGENXBIO is a leading biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® technology platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV technology platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV technology platform licensees.
Something looks off?On-site & Remote